ICU Medical’s (ICUI) Hold Rating Reiterated at Needham & Company LLC

ICU Medical (NASDAQ:ICUI)‘s stock had its “hold” rating reissued by Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports.

Several other research firms have also weighed in on ICUI. KeyCorp lifted their price objective on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Jefferies Financial Group assumed coverage on shares of ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. StockNews.com lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Raymond James lifted their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $170.25.

ICU Medical Stock Down 0.1 %

Shares of NASDAQ ICUI opened at $178.01 on Wednesday. The firm has a market capitalization of $4.35 billion, a PE ratio of -60.96 and a beta of 0.66. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. ICU Medical has a 1 year low of $79.85 and a 1 year high of $188.53. The firm’s 50-day moving average is $175.85 and its 200-day moving average is $141.75.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.35. The company had revenue of $580.07 million for the quarter, compared to analyst estimates of $574.77 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. Equities analysts expect that ICU Medical will post 3.81 EPS for the current year.

Insiders Place Their Bets

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,502 shares of company stock worth $8,445,976. Company insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Institutional investors have recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC increased its holdings in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 122 shares during the last quarter. Allworth Financial LP boosted its position in ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 100 shares during the period. Innealta Capital LLC bought a new position in ICU Medical during the second quarter worth $32,000. Motco bought a new position in ICU Medical during the first quarter worth $29,000. Finally, Venturi Wealth Management LLC boosted its position in ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 302 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.